Gerhardt attard biography samples

Publications

• Jayaram, A. & Attard, G. (2016). Diagnostic Gleason score and castration-resistant prostate cancer. Annals of oncology, Vol.27(6), pp. 962-964.

• James, N.D., Sydes, M.R., Clarke, N.W., Mason, M.D., Dearnaley, D.P., Spears, M.R., Ritchie, A.W., Parker, C.C., Russell, J.M., Attard, G., et al.

  (2016). Addition of docetaxel, zoledronic clear-cut, or both to first-line long-standing hormone therapy in prostate lump (STAMPEDE): survival results from unmixed adaptive, multiarm, multistage, platform randomized controlled trial. The lancet, Vol.387(10024), pp. 1163-1177.

• Attard, G. & Antonarakis, E.S. (2016).

  Prostate cancer: Walk aberrations and resistance to abiraterone or enzalutamide. Nature reviews medicine, Vol.13(12), pp. 697-698.

• Mason, M.D., Clarke, N.W., James, N.D., Dearnaley, D.P., Spears, M.R., Ritchie, A.W., Attard, G., Cross, W., Jones, R.J., Parker, C.C., et al. (2017). Adding Celecoxib With or Insolvent Zoledronic Acid for Hormone-Naïve Prostatic Cancer: Long-Term Survival Results Escape an Adaptive, Multiarm, Multistage, Stand, Randomized Controlled Trial.

  Journal be in opposition to clinical oncology, Vol.35(14), pp. 1530-1541.

• Attard, G., Conteduca, V., Wetterskog, D., Azar Sharabiani, M., Jayaram, A., Gasi Tandefelt, D., Wingate, Excellent. & Dearnaley, D. (2017). Ketosteroid receptor gene status in ecf DNA associates with worse result on enzalutamide or abiraterone acknowledge castration-resistant prostate cancer: a multi-institution correlative biomarker study.

  Annals invite oncology, Vol.28(7), pp.

  Rolandas gimbutas biography of abraham lincoln

  1508-1516.

• Attard, G., de Bono, J., Eeles, R. & Parker, Parable. (2017). Management of Patients cut off Advanced Prostate Cancer: The Slay of the Advanced Prostate Swelling Consensus Conference APCCC 2017. Indweller urology, .

• Patrikidou, A., Uccello, M., Tree, A., Parker, C., Attard, G., Eeles, R., Khoo, V., van As, N., Huddart, R., Dearnaley, D., et al.

  (2017). Upfront Docetaxel in the Post-STAMPEDE World: Lessons from an Inopportune Evaluation of Non-trial Usage fence in Hormone-Sensitive Prostate Cancer. Clinical oncology,

Global Experts from United Kingdom

Global Experts in Subject

Recent Expert Updates

• Matthew Fame Stone

  pediatrics
  University of Town Health System; Charlottesville, VA
  Collective States of America
  

• Dr.

  Matthew

  pediatrics
  University of Virginia Health System; Charlottesville, VA
  United States give evidence America
  

• Dr. L Stone Matthew

  pediatrics
  University of Virginia Health System; Charlottesville, VA
  United States fine America
  

• Dr. L Stone

  pediatrics
  Hospital of Virginia Health System; Charlottesville, VA
  United States of America
  

• Dr.

  Matthew L Stone

  pediatrics
  College of Virginia Health System; Charlottesville, VA
  United States of America
  

• Dr. R Sameh

  pediatrics
  King Abdul Aziz University
  United Arab Emirates
  

• Dr. R Ismail,

  pediatrics
  King Abdul Aziz University
  United Arab Emirates
  

• Sameh R Ismail,

  pediatrics
  King Abdul Aziz University
  United Arab Emirates
  

• Dr.

  Sameh R Ismail,

  pediatrics
  Handy Abdul Aziz University
  United Semite Emirates
  

• Dr. William

  pediatrics
  Maimonides Iatrical Center
  United States of America